Get the Stockscreener App
32.29
1.19%
0.38
Vaxcyte Inc stock is traded at $32.29, with a volume of 1.52M.
It is up +1.19% in the last 24 hours and down -9.60% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$31.91
Open:
$31.82
24h Volume:
1.52M
Relative Volume:
0.99
Market Cap:
$4.19B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-7.0196
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-1.25%
1M Performance:
-9.60%
6M Performance:
-59.51%
1Y Performance:
-58.68%
1-Day Range:
$31.77
$33.27
1-Week Range:
$30.69
$33.27
52-Week Range:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
32.29 | 4.17B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Reversal Confirmed Vaxcyte Inc. Stock Rallies Above MATrade Risk Report & Risk Adjusted Buy/Sell Alerts - newsyoung.net
Are Bears Losing Grip on Vaxcyte Inc.Market Risk Summary & High Accuracy Swing Trade Signals - kangso.co.kr
Vaxcyte Inc. Ranks High in Smart Money TrackerWeekly Trend Report & Verified Trade Idea Suggestions - newsyoung.net
Is Vaxcyte Inc. in Accumulation Phase Now2025 Market Overview & Real-Time Volume Surge Alerts - kangso.co.kr
Mizuho Securities Reiterates Buy Rating for Vaxcyte with $163 Price Target - AInvest
Can Vaxcyte Inc. deliver alphaPortfolio Gains Summary & High Accuracy Trade Alerts - metrotimes.co.kr
Vaxcyte Inc. Flashes Rebound Signal in Oversold ConditionQuarterly Profit Report & Weekly Breakout Opportunity Watchlist - metal.it
Vaxcyte Inc. Shows Support at Fibonacci LevelQuarterly Earnings Report & Low Risk Investment Opportunities - beatles.ru
Vaxcyte Q2 Earnings: Progress in Vaccine Development and $2.8 Billion Cash Position - AInvest
Why Vaxcyte’s Stock is on the Rise - TipRanks
Vaxcyte Inc. Rebounds From Oversold Zone — Now WhatTriple Digit Growth Focused Trade Plan Reviewed - 선데이타임즈
Vaxcyte Reports Progress in Vaccine Development - TipRanks
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $116 - 富途牛牛
Guggenheim lowers Vaxcyte stock price target to $116 on trial timeline shifts - Investing.com Canada
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Pipeline Insight into Pneumococcal Disease Treatments: Sanofi, Alopexx, and Virometix Lead the Way - AInvest
Vaxcyte, Inc. shares fall 9.56% intraday after FDA interactions and Phase 3 clinical program finalization. - AInvest
Vaxcyte price target lowered to $50 from $85 at TD Cowen - TipRanks
Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating - TipRanks
Vaxcyte Q2 Loss Widens 11%, Ends Quarter with $2.83B in Cash - AInvest
Vaxcyte Q2 EPS $1.22, beats consensus $1.16; CEO discusses Phase 3 program for VAX-31. - AInvest
Vaxcyte (PCVX) Q2 Loss Widens 11% - AOL.com
Vaxcyte (PCVX) Q2 Loss Widens 11% - The Motley Fool
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating - TipRanks
Vaxcyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) - GlobeNewswire
MACD Signals Flash Warning for Vaxcyte Inc. StockMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What is the dividend policy of Vaxcyte Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
How strong is Vaxcyte Inc. company’s balance sheetUnprecedented profits - Jammu Links News
How does Vaxcyte Inc. compare to its industry peersDiscover stocks with explosive upside potential - Jammu Links News
Is Vaxcyte Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - Jammu Links News
Is Vaxcyte Inc. a growth stock or a value stockFree Investment Risk Control - Jammu Links News
How does Vaxcyte Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Vaxcyte Inc. stock expected to show significant growthUnlock powerful stock screening tools today - Jammu Links News
Is it the right time to buy Vaxcyte Inc. stockDiscover stocks with explosive growth potential - Jammu Links News
What drives Vaxcyte Inc. stock priceInvest smarter with real-time trading signals - Jammu Links News
What are the latest earnings results for Vaxcyte Inc.Stay ahead with advanced stock screening tools - Jammu Links News
What are analysts’ price targets for Vaxcyte Inc. in the next 12 monthsBuild a diversified portfolio for steady growth - Jammu Links News
Should I hold or sell Vaxcyte Inc. stock in 2025Phenomenal capital appreciation - Jammu Links News
What institutional investors are buying Vaxcyte Inc. stockPowerful profit generation - Jammu Links News
Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants - MSN
InvestingPro’s Fair Value model predicted Vaxcyte’s 46% decline By Investing.com - Investing.com
What markets is Vaxcyte Inc. expanding into Is FDUS stock a good long term investment optionFree Stock Target Finder That Work - Jammu Links News
We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth - 富途牛牛
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Vaxcyte Inc. stock price move sharplyMarket Entry and Exit Point Tips From Traders - metal.it
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):